上尿路尿路上皮癌输尿管镜治疗后的膀胱内复发:一项荟萃分析
本荟萃分析纳入24项研究共1904例上尿路尿路上皮癌患者,评估输尿管镜激光消融对肿瘤学结局的影响。总体膀胱内复发率为23.7%,输尿管镜与根治性肾输尿管切除术在膀胱内复发和总生存上无统计学显著差异。输尿管镜可不损害肿瘤学结局。
要点
- 输尿管镜激光消融后膀胱内复发总体率为23.7%。
- 输尿管镜与根治性肾输尿管切除术在膀胱内复发和总生存上无显著差异。
- 输尿管镜可不损害上尿路尿路上皮癌患者的肿瘤学结局。
核心结论
- 输尿管镜激光消融对膀胱内复发率影响可忽略,且与根治性肾输尿管切除术相比膀胱内复发和总生存无统计学显著差异。
- 输尿管镜可在不损害肿瘤学结局的情况下实施。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA声明,PROSPERO注册号CRD42025642480。
- 最终纳入24项研究,共1904例上尿路尿路上皮癌患者。
主要发现
- 总体膀胱内复发率为23.7%(n=453)。
- 总体 pooled 分析:膀胱内复发效应量0.33,根治性肾输尿管切除术与治疗比0.23,总生存效应量0.62(均P≤0.005)。
- 输尿管镜与根治性肾输尿管切除术比较:膀胱内复发效应量1.14,总生存效应量1.43(均P>0.05)。
- 术后灌注亚组:膀胱内复发效应量0.38(P=0.029),根治性肾输尿管切除术与治疗比0.25(P=0.012)。
临床怎么用
- 对于上尿路尿路上皮癌患者,输尿管镜激光消融可作为不损害肿瘤学结局的治疗选择。
- 术后灌注可能影响膀胱内复发和根治性肾输尿管切除术与治疗比,需结合亚组结果个体化考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the role of ureteroscopy (URS) with laser ablation on oncological outcomes, namely, intravesical recurrence (IVR) rate, radical nephroureterectomy (RNU)-to-treat ratio and overall survival (OS), in patients with upper tract urothelial carcinoma (UTUC), an area of study that has been insufficiently addressed in the literature. MATERIALS AND METHODS: A systematic search (PROSPERO: CRD42025642480) was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. A pooled analysis was performed to quantify the effect size (ES) for IVR rate, radical nephroureterectomy (RNU)-to-treat ratio and OS. Subgroup analyses were performed to evaluate patients who received postoperative instillations and to compare URS with laser ablation to RNU. RESULTS: Overall, 24 studies involving 1904 patients were included in the final analysis. The overall rate of IVR was 23.7% (n = 453). The overall pooled analysis showed an ES for IVR of 0.33, for RNU-to-treat ratio of 0.23, and for OS of 0.62 (all P ≤ 0.005). In the comparison between URS and RNU, the pooled ES of URS for IVR was 1.14 and for OS it was 1.43 (all P > 0.05). Within the subgroup analysis of patients who received postoperative instillations, the pooled ES for IVR was 0.38 (P = 0.029) and for RNU-to-treat ratio it was 0.25 (P = 0.012). CONCLUSIONS: In this systematic review, URS with laser ablation was found to exert a negligible effect on IVR rate. Moreover, no statistically significant differences in IVR nor in OS were recorded when URS was compared to RNU. URS can be performed without compromising the oncological outcomes of patients with UTUC.
引用
- Di Bello F, Gallioli A, Cannoletta D, et al. Intravesical recurrence after therapeutic ureteroscopy for upper tract urothelial carcinoma: a meta-analysis. BJU Int. 2025. PMID: 40877028. doi:10.1111/bju.16902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。